Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan. It is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; FLU Quadrivalent, which is in Phase III clinical trial for the treatment of influenza viruses; dengue vaccine, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. Medigen Vaccine Biologics Corporation was incorporated in 2012 and is headquartered in Zhubei City, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.